Molecular genotyping in medullary thyroid cancer

被引：2

作者：

Newbold, Kate ^{[1
,2
]}

机构：

[1] Royal Marsden NHS Fdn Trust Hosp, London, England

[2] Royal Marsden NHS Fdn Trust Hosp, Consultant Clin Oncologist, Fulham Rd, London SW3 6JJ, England

来源：

CURRENT OPINION IN ONCOLOGY | 2023年 / 35卷 / 01期

关键词：

medullary thyroid cancer; rearranged during transfection; ACQUIRED-RESISTANCE; RET PROTOONCOGENE; RAS MUTATIONS; CARCINOMA; ACTIVATION; SELPERCATINIB; CABOZANTINIB;

D O I：

10.1097/CCO.0000000000000915

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of reviewThere has been a significant advance in our understanding of the molecular biology of medullary thyroid cancer (MTC) alongside progress in the development of targeted therapies including multikinase and specific rearranged during transfection inhibitors.Recent findingsThis review will examine the latest data investigating the impact of the genomics of MTC on the prediction of the natural history of an individual's disease and the determination, selection and timing of treatment interventions.Recent advances in genotyping in MTC and the development of targeted therapies have impacted on the clinical management of both sporadic and hereditary MTC.

引用

页码：10 / 14

页数：5

共 50 条

[31] Prophylactic thyroidectomy in medullary thyroid cancer
Peix, Jean-Louis
Lifante, Jean Christophe
Chazot, Francoise Borson
Giraud, Sophie
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2012, 196 (07): : 1247 - 1258
[32] Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, Rossella
Schlumberger, Martin J.
Mueller, Stefan P.
Schoffski, Patrick
Brose, Marcia S.
Shah, Manisha H.
Licitra, Lisa
Jarzab, Barbara
Medvedev, Viktor
Kreissl, Michael C.
Niederle, Bruno
Cohen, Ezra E. W.
Wirth, Lori J.
Ali, Haythem
Hessel, Colin
Yaron, Yifah
Ball, Douglas
Nelkin, Barry
Sherman, Steven I.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3639 - +
[33] The Surgical Management of Medullary Thyroid Cancer
Dackiw, Alan P. B.
OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2010, 43 (02) : 365 - +
[34] Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies
Yeh, Tiffany
Yeung, Michele
Sherman, Eric J.
Tuttle, R. Michael
Sabra, Mona M.
THYROID, 2020, 30 (08) : 1112 - 1119
[35] Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy
Hincza-Nowak, Kinga
Kowalik, Artur
Walczyk, Agnieszka
Palyga, Iwona
Gasior-Perczak, Danuta
Plusa, Agnieszka
Kopczynski, Janusz
Chrapek, Magdalena
Gozdz, Stanislaw
Kowalska, Aldona
GENES, 2021, 12 (10)
[36] Different outcomes in sporadic versus familial medullary thyroid cancer
Saltiki, Katerina
Simeakis, George
Anagnostou, Elli
Zapanti, Evangelia
Anastasiou, Eleni
Alevizaki, Maria
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (01): : 154 - 161
[37] Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer
Bastholt, Lars
Kreissl, Michael C.
Fuehrer, Dagmar
Maia, Ana L.
Locati, Laura D.
Maciel, Lea
Wu, Yi
Heller, Kevin N.
Webster, Alan
Elisei, Rossella
EUROPEAN THYROID JOURNAL, 2016, 5 (03) : 187 - 194
[38] MEDULLARY THYROID CANCER - FEATURE REVIEW AND UPDATE ON SYSTEMIC TREATMENT
Dabelic, Nina
Jukic, Tomislav
Frobe, Ana
ACTA CLINICA CROATICA, 2020, 59 : 50 - 59
[39] Medullary thyroid carcinoma
Jaber, Tania
Dadu, Ramona
Hu, Mimi, I
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2021, 28 (05) : 540 - 546
[40] Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer
Sherman, Steven I.
ORAL ONCOLOGY, 2013, 49 (07) : 707 - 710

← 1 2 3 4 5 →